ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 01/09/23

Takeda ( NYSE: TAK ) and Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) reported data from a phase 2 trial of fazirsiran (TAK-999/ARO-AAT) to treat liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD). Alpha-1 antitrypsin protein (AAT) is made in the liv...

Stocks To Watch: Citigroup, Wells Fargo And JPMorgan Lead off Earnings Season Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, inclu...

Summary My portfolio, built specifically for my retirement ~20+ years from now gets a nice end-of-the-year Petrobras dividend to help ease market pain. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping creat...

Summary Arrowhead is a strong biotech with unique and powerful attributes. The company has seen its share of recent struggles, including in share price. It leverages its RNAi technology to develop drugs with the potential to treat very serious diseases. Arrowhead has tightened i...

- Announcement on January 9, 2023, with Webcast at 8:30 a.m. ET Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on January 9, 2023, at 8:30 a.m. ET, it will present topline data from the SEQUOIA Phase 2 study evaluating fazirsiran and provide an outline of a Phase 3 stu...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced a $25M milestone payment from Amgen (NASDAQ: AMGN). This milestone was triggered by the first subject enrolled in Amgen’s Phase 3 trial of olpasiran. Arrowhead is further eligible to receive up to an additional $535 million in a...

- Arrowhead Earns $15 million Milestone from Horizon Therapeutics plc Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Horizon Therapeutics plc (Nasdaq: HZNP) has enrolled the first subject, earning Arrowhead a $15 million milestone payment, in a Phase 1 randomized, plac...

- Conference Call and Webcast Today, November 28, 2022 at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2022. The company is hosting a conference call today, November 28, 2022, at 4:30 p.m. E...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: Piper Sandler 34 th Annual Healthcare Conference – November 30, 2022 Type: Fireside chat presentation Presenter: Christo...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 28, 2022, at 4:30 p.m. ET to discuss its financial results for the 2022 fiscal year ended September 30, 2022. Webcast and Conference Call and Details Inv...